Vaxcyte, Inc. (PCVX)
71.38
+6.36
(+9.79%)
USD |
NASDAQ |
Oct 09, 16:00
71.27
-0.11
(-0.15%)
After-Hours: 20:00
Vaxcyte Cash from Operations (Quarterly) : -232.47M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -232.47M |
| March 31, 2026 | -280.62M |
| December 31, 2025 | -224.83M |
| September 30, 2025 | -143.30M |
| June 30, 2025 | -121.17M |
| March 31, 2025 | -166.27M |
| December 31, 2024 | -111.40M |
| September 30, 2024 | -60.71M |
| June 30, 2024 | -121.39M |
| March 31, 2024 | -159.12M |
| December 31, 2023 | -128.81M |
| September 30, 2023 | -57.55M |
| June 30, 2023 | -62.74M |
| March 31, 2023 | -47.69M |
| December 31, 2022 | -65.22M |
| Date | Value |
|---|---|
| September 30, 2022 | -38.55M |
| June 30, 2022 | -39.13M |
| March 31, 2022 | -27.70M |
| December 31, 2021 | -51.09M |
| September 30, 2021 | -28.42M |
| June 30, 2021 | -28.68M |
| March 31, 2021 | -13.20M |
| December 31, 2020 | -10.77M |
| September 30, 2020 | -13.06M |
| June 30, 2020 | -9.069M |
| March 31, 2020 | -13.74M |
| December 31, 2019 | -15.50M |
| September 30, 2019 | -9.458M |
| June 30, 2019 | -13.51M |
| March 31, 2019 | -9.768M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Moderna, Inc. | -526.00M |
| Vir Biotechnology, Inc. | 123.33M |
| Revolution Medicines, Inc. | -387.32M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 147.72M |
| Cash from Financing (Quarterly) | 5.701M |
| Free Cash Flow | -921.07M |
| Free Cash Flow Per Share (Quarterly) | -1.640 |
| Free Cash Flow to Equity (Quarterly) | -236.19M |
| Free Cash Flow to Firm (Quarterly) | -237.04M |
| Free Cash Flow Yield | -9.36% |